- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.04. | MAIA Biotechnology opens first U.S. site for lung cancer trial | 1 | Investing.com | ||
| 16.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer | 192 | GlobeNewswire (Europe) | Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC... ► Artikel lesen | |
| 16.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | MAIA Biotechnology expects $33M capital raise to fund Phase 3 trial of anticancer therapy | 1 | Seeking Alpha | ||
| 08.04. | MAIA Biotechnology, Inc.: MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy | 167 | GlobeNewswire (Europe) | Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probability... ► Artikel lesen | |
| 08.04. | MAIA Biotechnology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | MAIA Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| MAIA BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 31.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer | 359 | GlobeNewswire (Europe) | Potential breakthrough therapeutic targets $50B+ global immunotherapy market1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a... ► Artikel lesen | |
| 27.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.03. | MAIA Biotechnology, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 04.03. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 03.03. | MAIA Biotechnology slides after pricing offering to raise $30M | 2 | Seeking Alpha | ||
| 03.03. | MAIA Biotechnology Prices $30 Mln Public Offering Of Shares At $1.50/shr; Stock Down | 2 | RTTNews | ||
| 03.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock | 237 | GlobeNewswire (Europe) | Financing included participation by healthcare-dedicated investors alongsideexisting shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA"... ► Artikel lesen | |
| 02.03. | MAIA Biotechnology, Inc.: MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants | 159 | GlobeNewswire (Europe) | CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies... ► Artikel lesen | |
| 24.02. | MAIA Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.02. | MAIA Biotechnology, Inc.: MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market | 398 | GlobeNewswire (Europe) | Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine... ► Artikel lesen | |
| 20.01. | MAIA Biotechnology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.01. | MAIA Biotechnology, Inc.: MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | 526 | GlobeNewswire (Europe) | High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine... ► Artikel lesen |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 111,90 | +0,34 % | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the... ► Artikel lesen | |
| ABBVIE | 180,75 | +0,33 % | AbbVie Canada: AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec | National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec.Award provides RIME Therapeutics with a year of laboratory... ► Artikel lesen | |
| ABBOTT LABORATORIES | 77,32 | +0,03 % | Abbott Wins FDA Clearance, CE Mark For Ultreon 3.0 Coronary Imaging Platform | NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) on Tuesday said it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon 3.0 AI-powered coronary... ► Artikel lesen | |
| SCHOTT PHARMA | 14,940 | +2,05 % | BARCLAYS stuft Schott Pharma auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Schott Pharma von 15 auf 16 Euro angehoben, aber die Einstufung auf "Equal Weight" belassen. Im Bereich der Pharma-Verpackungsspezialisten... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 70,94 | -0,31 % | Edwards Lifesciences Corp. Q1 Income Rises | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) released a profit for its first quarter that Increases, from the same period last yearThe company's earnings came in at $380.7 million... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 22,650 | -0,88 % | Assembly Biosciences-Aktie: "Weitere signifikante Meilensteine" erwartet | Für Aktionäre von Assembly Biosciences war 2025 ein Jahr, das den strategischen Kurs des Unternehmens eindrucksvoll bestätigte. Mehrere klinische Programme lieferten positive Daten, teilweise sogar... ► Artikel lesen | |
| PENTIXAPHARM | 2,100 | -0,94 % | PTA-HV: Pentixapharm Holding AG: Einladung zur Hauptversammlung | DJ PTA-HV: Pentixapharm Holding AG: Einladung zur Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Pentixapharm Holding AG: Einladung zur Hauptversammlung
Berlin (pta000/29.04.2026/16:00... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,268 | +2,26 % | FILANA THERAPEUTICS, INC. - 8-K, Current Report | ||
| AXSOME THERAPEUTICS | 177,00 | -0,08 % | XFRA 19X: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAXSOME THERAPEUT.... ► Artikel lesen | |
| MEDPACE | 357,00 | 0,00 % | Medpace Holdings Inc. (MEDP): Bares Capital Trims Stake | ||
| ZEALAND PHARMA | 40,900 | +0,62 % | Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management | Company announcement - No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management Phase 3 trials for chronic weight management... ► Artikel lesen | |
| UNITED THERAPEUTICS | 494,60 | +1,56 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| UCB | 231,60 | +0,26 % | UCB presentation highlights impacts of epilepsy on daily life | ||
| MADRIGAL PHARMACEUTICALS | 442,80 | +0,48 % | MADRIGAL PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| BRIDGEBIO PHARMA | 61,17 | +0,96 % | BridgeBio Pharma, Inc.: BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET |
Das Unternehmen MAIA BIOTECHNOLOGY INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+1,50 %) liegt der Kurs bei 1,355 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAIA BIOTECHNOLOGY INC finden Sie auf Wallstreet Online.